|04/10/14||AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC|
|Biodesix to Fund Proof of Concept Study
CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--Apr. 10, 2014--
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that
they have entered into a worldwide agreement to develop and
commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody
ficlatuzumab, with a Biodesix® companion diagnostic test.
This agreement and the clinical development program will leverage
|03/20/14||AVEO Regains Worldwide Rights to AV-203|
|Agreement with Biogen Idec allows AVEO to seek partner to accelerate
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2014--
AVEO Oncology (NASDAQ: AVEO) today announced that it has regained
worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory
antibody candidate, from Biogen Idec.
“We are pleased to regain rights for AV-203 as we believe in the
potential of this innovative therapy and are looking forward... |
|03/13/14||AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan|
|- Company ends 2013 with $118M in cash1 -
- Focuses internal R&D investment on AV-380 in cachexia -
- Intends to advance clinical-stage assets through strategic
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2014--
AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2013 financial
results and outlined its 2014 strategic plan and financial guidance.
“With the cost-containment measures implemented in th... |